Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options
LAS VEGAS, May 13, 2025 /PRNewswire/ -- Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage. This abnormal wound-healing response distorts the liver's structure, potentially progressing to cirrhosis, portal hypertension, and ultimately liver failure.
Previously, liver steatosis was categorized as NAFLD and its more inflammatory subtype, NASH. However, to better reflect its metabolic roots, updated terminology such as MASLD and MASH has been introduced. These, along with other classifications like MASL, NASL, and MetALD, fall under the broader umbrella of Steatotic Liver Disease (SLD), offering improved diagnostic precision by emphasizing metabolic dysfunction. DelveInsight's assessment estimated around 8.3 million diagnosed prevalent cases of liver fibrosis across the seven major markets in 2024, with this figure expected to rise by 2034.
Management of liver fibrosis involves a multifaceted approach due to its complex nature. Treatments include biological and pharmacological therapies, lifestyle and dietary changes, and surgical interventions, all aimed at halting disease progression and preserving liver function. Key therapeutic targets include fibrogenic pathways such as LOXL2 inhibition, antiviral treatments for viral causes, FXR agonists like obeticholic acid, and metabolic modulators to reduce inflammation and fibrotic buildup. Tailoring therapies to the underlying cause of fibrosis is crucial, underscoring the importance of personalized treatment strategies.
To know more about liver fibrosis treatment options, visit @ New Treatment for Liver Fibrosis
The approval of REZDIFFRA (resmetirom) in March 2024 represents a major advancement in the treatment of noncirrhotic MASH with moderate to advanced fibrosis. This groundbreaking therapy targets the root causes of MASH and brings renewed hope to patients affected by the condition. Clinical trials have shown impressive results, with REZDIFFRA significantly reducing inflammation and fibrosis, improving liver function, and enhancing patients' quality of life. Its approval marks a critical addition to the limited treatment options available, with the potential to lessen complications from progressive liver disease.
Madrigal Pharmaceuticals aims to roll out REZDIFFRA across Europe starting with Germany in the second half of 2025, pending EMA approval for REZDIFFRA, making it the first authorized therapy for MASH-related liver fibrosis in the region. Furthermore, updated two-year data from the MAESTRO-NAFLD-1 trial, released in February 2025, indicate possible benefits for patients with compensated MASH cirrhosis, suggesting an expanded scope of clinical effectiveness.
Madrigal's choice to commercialize REZDIFFRA independently in Europe presents both potential benefits and notable challenges. On one hand, it enables the company to retain full control and capture the entire value of the product. On the other, it faces the complexities of navigating Europe's fragmented healthcare landscape without a regional partner, which heightens the uncertainty around regulatory approvals and market uptake.
The company expects a decision from the European Medicines Agency (EMA) by mid-2025, with launches rolling out on a country-by-country basis, starting in Germany in the second half of 2025. If approved, Madrigal Pharmaceutical's REZDIFFRA would become the first authorized treatment for MASH liver fibrosis in Europe.
Learn more about the FDA-approved liver fibrosis drugs @ Drugs for Liver Fibrosis Treatment
The treatment landscape is evolving rapidly, with various competitive threats emerging. Notable competitors include Inventiva Pharma's Lanifibranor (IVA337), Akero Therapeutics' Efruxifermin, Sagimet Biosciences' Denifanstat, 89bio's Pegozafermin, Novo Nordisk's WEGOVY (semaglutide), and others.
In addition, several liver fibrosis drugs are currently being developed at various stages, including HU6 from Rivus Pharmaceuticals, LPCN 1144 from Lipocine, MN-001 from MediciNova, Icosabutate from NorthSea Therapeutics, Lixudebart (ALE.F02) from Alentis Therapeutics, PHIN-214 from PharmaIN, and FXR314 from Organovo.
Competing liver fibrosis therapies in advanced clinical stages, including Inventiva's lanifibranor and Akero Therapeutics' efruxifermin, pose direct competition. Lanifibranor, in particular, offers a differentiated pan-PPAR agonist approach, potentially competing with REZDIFFRA's efficacy and safety profile.
Discover which therapies are expected to grab major liver fibrosis market share @ Liver Fibrosis Market Report
Efruxifermin (EFX) is Akero Therapeutics' primary candidate for MASH treatment. This Fc-FGF21 fusion protein is designed to replicate the natural activity of FGF21, a hormone that reduces cellular stress and helps regulate metabolism. EFX offers the convenience of once-weekly subcutaneous injections and is being developed for pre-cirrhotic MASH (F2-F3) and compensated cirrhosis due to MASH (F4). Early results suggest that EFX could potentially become a leading treatment for MASH if approved. In January 2025, Akero Therapeutics announced the completion of patient enrollment in the Phase III SYNCHRONY Real-World study for MASH or MASLD (F1-F4), with results expected in the first half of 2026.
Pegozafermin (BIO89-100) is a compound that activates the fibroblast growth factor 21 (FGF21) receptor, a hormone involved in glucose and lipid metabolism. It has shown promise as a therapeutic for MASH. In January 2025, the company emphasized its strong position for the year, with ongoing Phase III trials in MASH. It expects to release topline data from its first Phase III trial in late 2025. The company is also conducting two Phase III trials—ENLIGHTEN-Fibrosis for non-cirrhotic MASH (F2-F3) patients and ENLIGHTEN-Cirrhosis for compensated cirrhotic MASH (F4) patients—both of which are actively enrolling global patients.
BOS-580 (Efimosfermin Alfa) is a long-acting, once-monthly FGF21 analogue in development for MASH. This investigational fusion protein targets three FGF21 receptors for a balanced pharmacological effect. In November 2024, Boston Pharmaceuticals reported positive Phase II data for BOS-580 in F2/F3 MASH at AASLD 2024. The treatment showed significant improvement in fibrosis (≥1 stage) with no worsening of MASH after 24 weeks. Two-thirds of patients treated with BOS-580 achieved significant MASH resolution without worsening fibrosis, compared to placebo. The Phase II trial also showed reductions in liver injury markers, fibrosis, and improvements in metabolic health. BOS-580 has demonstrated low discontinuation rates in clinical trials, with gastrointestinal issues being the most common side effects. In June 2024, data presented at EASL Congress 2024 highlighted significant improvements in lipid profiles with BOS-580 treatment.
Denifanstat, a selective fatty acid synthase (FASN) inhibitor, is advancing in Phase III trials for MASH, targeting De Novo Lipogenesis (DNL) to reduce palmitate production. In October 2024, Sagimet Biosciences concluded successful end-of-Phase II discussions with the US FDA, moving denifanstat into Phase III trials. The FASCINATE-3 trial focuses on non-cirrhotic MASH (F2/F3), and FASCINIT examines patients with suspected or confirmed MASLD/MASH. In February 2025, Sagimet announced lipidomic data from the Phase IIb FASCINATE-2 trial, focusing on triglycerides and LDL cholesterol in advanced fibrosis, which will be presented at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium. The US FDA granted denifanstat Breakthrough Therapy (BTD) and Fast Track Designation (FTD) for non-cirrhotic MASH with moderate to advanced fibrosis.
Survodutide, a dual GLP-1/glucagon receptor agonist, is also in Phase III development for MASH and fibrosis, targeting key metabolic pathways. In October 2024, Boehringer Ingelheim initiated the LIVERAGE trials, including LIVERAGE for MASH with fibrosis and LIVERAGE-Cirrhosis for MASH with cirrhosis. The US FDA granted Survodutide BTD for non-cirrhotic MASH with fibrosis, while the European Medicines Agency (EMA) included it in its Priority Medicines (PRIME) scheme for NASH. Boehringer Ingelheim and Zealand Pharma received US FDA support, highlighting Survodutide's potential to address unmet needs in MASH treatment.
Discover more about drugs for liver fibrosis in development @ Liver Fibrosis Clinical Trials
The anticipated launch of these emerging therapies for liver fibrosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the liver fibrosis treatment market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for liver fibrosis is expected to grow from USD 2.1 billion in 2024, with a significant CAGR of ~24% by 2034. This anticipated growth in the liver fibrosis market is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of liver fibrosis, which together foster higher demand for innovative and effective therapies.
DelveInsight's latest published market report, titled as Liver Fibrosis Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the liver fibrosis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The liver fibrosis market forecast report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Liver Fibrosis Diagnosed Prevalent Cases
Liver Fibrosis Severity-specific Diagnosed Prevalent Cases
Total Liver Fibrosis Diagnosed Prevalent Cases (≥F2 Stage) in MASH
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM liver fibrosis market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this liver fibrosis market forecast report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the liver fibrosis treatment market. Also, stay abreast of the mitigating factors to improve your market position in the liver fibrosis therapeutic space.
Related Reports
Liver Fibrosis Pipeline
Liver Fibrosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key liver fibrosis companies, including Galmed Research and Development, Ltd, AstraZeneca, Galectin Therapeutics, Resolution Therapeutics, AdAlta, Novo Nordisk A/S, Sagimet Biosciences Inc., Hepion Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Inipharm, GAT Therapeutics, TiumBio, INVENT Pharmaceuticals, SFA Therapeutics, among others.
Non-Alcoholic Fatty Liver Disease Market
Non-Alcoholic Fatty Liver Disease Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key NAFLD companies, including MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., among others.
Metabolic Dysfunction-Associated Steatohepatitis Market
Metabolic Dysfunction-Associated Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key MASH companies, including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, among others.
Nonalcoholic Steatohepatitis Pipeline
Nonalcoholic Steatohepatitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/liver-fibrosis-market-to-witness-rapid-growth-at-a-cagr-of-24-during-the-forecast-period-20252034-with-emerging-treatment-options--delveinsight-302453339.html
SOURCE DelveInsight Business Research, LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Madrigal Pharmaceuticals, Inc. (MDGL)'s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
We recently compiled a list of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It's FDA-approved drug, Rezdiffra (resmetirom), is the first oral, liver-targeted thyroid hormone receptor-β agonist for MASH with moderate to advanced fibrosis (F2–F3). It is also being tested in compensated MASH cirrhosis patients. At the 2025 EASL Congress, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented promising two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, showing Rezdiffra significantly reduced liver stiffness and lowered the risk of liver decompensation in F4c patients. Notably, 51% of participants had a ≥25% reduction in liver stiffness, and 65% of those with baseline portal hypertension moved to lower-risk categories. Safety remained consistent with prior results. Looking ahead, the MAESTRO-NASH OUTCOMES trial, expected to read out in 2027, will evaluate Rezdiffra's ability to reduce liver-related events in compensated cirrhosis patients. Meanwhile, regulatory momentum continues: the EMA's CHMP issued a positive opinion in June 2025, with potential EU approval expected by August. Rezdiffra would then be the first MASH treatment approved in both the U.S. and Europe. A healthcare professional wearing a health communications device discussing patient data with a colleague. Further solidifying its position, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) secured a new U.S. patent for Rezdiffra's dosing rights in July 2025, enhancing its intellectual property and global commercialization strategy. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity
The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launch of emerging therapies such as Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), and others, heightened UV exposure, advancements in diagnostic techniques, and lifestyle changes. New York, USA, July 22, 2025 (GLOBE NEWSWIRE) -- Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launch of emerging therapies such as Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), and others, heightened UV exposure, advancements in diagnostic techniques, and lifestyle changes. DelveInsight's Melanoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging melanoma drugs, market share of individual therapies, and current and forecasted Melanoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Melanoma Market Report According to DelveInsight's analysis, the total melanoma market size is expected to grow positively by 2034. The United States accounts for the largest market size of melanoma, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. In 2024, the total number of incident cases of melanoma was approximately 105K in the US. The trend indicates that melanoma occurs more frequently in males than in females, and around 20% of cases eventually progress to advanced stages (stage III/IV), involving unresectable or distant metastatic disease. Prominent companies, including Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others, are actively working on innovative melanoma drugs. Some of the key melanoma therapies in the pipeline include Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab, and others. These novel melanoma therapies are anticipated to enter the melanoma market in the forecast period and are expected to change the market. In May 2025, Immatics announced the presentation of expanded data from the ongoing Phase Ib clinical trial evaluating IMA203 in heavily pretreated patients with metastatic melanoma In April 2025, IDEAYA Biosciences announced a successful FDA Type D meeting on the Phase III registrational trial design that would assess the safety and efficacy of darovasertib for potential regulatory approval as neoadjuvant therapy for primary uveal melanoma. Discover which melanoma medications are expected to grab the market share @ Melanoma Market Report Melanoma Overview Melanoma is a type of skin cancer that originates in melanocytes, the pigment-producing cells responsible for giving skin its color. While it is less common than other skin cancers, melanoma is significantly more aggressive and has a higher risk of spreading to other parts of the body if not detected early. It can occur anywhere on the body but is most frequently found on areas exposed to the sun, such as the back, legs, arms, and face. The primary cause of melanoma is ultraviolet radiation from sunlight or artificial sources like tanning beds, which can damage the DNA in skin cells. Individuals with fair skin, a history of sunburns, a large number of moles, or a family history of melanoma are at higher risk. Genetic mutations, such as in the BRAF gene, also play a significant role in the development of melanoma in certain cases. Symptoms of melanoma often begin with changes in the appearance of a mole or pigmented area. Warning signs include asymmetry, irregular borders, color variation, a diameter larger than 6 mm, and evolving shape or size, summarized by the ABCDE rule. Itching, bleeding, or the appearance of a new mole can also be concerning signs. Diagnosis typically involves a thorough skin examination followed by a biopsy of any suspicious lesion. If melanoma is confirmed, further tests such as sentinel lymph node biopsy, imaging scans (CT, MRI, or PET), and blood work may be conducted to determine the stage and whether the cancer has spread. Early diagnosis is critical, as it significantly improves the prognosis and expands treatment Epidemiology Segmentation The melanoma epidemiology section provides insights into the historical and current melanoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The melanoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Melanoma Stage-specific Incident Cases of Melanoma Mutation-specific Incident Cases of Melanoma Line-wise Treated Cases of Melanoma Download the report to understand which factors are driving melanoma epidemiology trends @ Melanoma Treatment Algorithm Melanoma Treatment Market There remains a substantial unmet need for effective treatment options in melanoma patients who are resistant to, unsuitable for, or unresponsive to standard therapies like checkpoint inhibitors or BRAF/MEK-targeted treatments. The FDA has approved several therapies for melanoma, including AMTAGVI (lifileucel, Iovance Biotherapeutics), OPDUALAG (nivolumab + relatlimab, Bristol Myers Squibb), KEYTRUDA (pembrolizumab, Merck), OPDIVO (nivolumab, BMS), KIMMTRAK (tebentafusp-tebn, Immunocore), YERVOY (ipilimumab, BMS), TECENTRIQ (atezolizumab, Roche), among others. AMTAGVI, from Iovance Biotherapeutics, became the first FDA-approved, personalized, one-time T cell therapy in February 2024. It is intended for adults with unresectable or metastatic melanoma who have previously been treated with PD-1 inhibitors, and for those with BRAF V600 mutations, after BRAF inhibitor ± MEK inhibitor therapy. That same year, Iovance submitted a Marketing Authorization Application (MAA) for lifileucel to the EMA in June (validated in August) and to the UK's MHRA in October. In June 2025, Iovance announced that the final results from the Phase II C-144-01 trial of AMTAGVI in advanced melanoma patients were published in the Journal of Clinical Oncology and presented at the 2025 ASCO Annual Meeting. Bristol Myers Squibb's OPDUALAG combines nivolumab, a PD-1 inhibitor, with relatlimab, a LAG-3 inhibitor, and is indicated for the treatment of unresectable or metastatic melanoma. The FDA approved it in March 2022 for adults and children aged 12 and above. However, in February 2025, BMS reported that the Phase III RELATIVITY-098 trial did not achieve its primary endpoint of recurrence-free survival (RFS) in the adjuvant setting for completely resected stage III–IV melanoma, although the safety profile remained consistent with existing data on the combination. KEYTRUDA and OPDIVO both demonstrate strong efficacy in treating melanoma, though OPDIVO has gained greater commercial traction through effective combination regimens and broader clinical use. Despite metastatic melanoma often being incurable, the emergence of advanced treatments such as immune checkpoint inhibitors and targeted therapies has markedly improved survival and quality of life, signaling a significant evolution in the standard of care. Learn more about the melanoma treatment options @ Melanoma Treatment Guidelines Melanoma Emerging Drugs and Companies Some of the products in the pipeline include Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), RP1 (vusolimogene oderparepvec) plus nivolumab (Replimune and BMS), APG-115 (Ascentage Pharma), Naporafenib (ERAS-254) (Erasca), KB707 (Krystal Biotech), Darovasertib (IDE196) (IDEAYA Biosciences and Novartis), HBI-8000 (HUYA Bioscience and BMS), Fianlimab (Regeneron Pharmaceuticals), and others. IMA203 is a TCR T-cell therapy that targets the Preferentially Expressed Antigen in Melanoma (PRAME). It's designed to identify an intracellular PRAME-derived peptide displayed on the surface of cells by HLA-A*02:01, triggering a strong and specific anti-tumor immune response. Encouraging Phase Ib results, along with PRAME's high expression rate in melanoma (~90–95%), support IMA203's therapeutic promise. The therapy is currently under investigation in the SUPRAME Phase III trial (NCT06743126) for previously treated advanced or metastatic cutaneous melanoma, and its Phase Ib expansion now includes uveal melanoma. According to the company's 2024 Annual Report, interim analysis for IMA203 is expected in Q1 2026, with final Phase III results in Q4 2026. A Biologics License Application (BLA) submission is planned for Q1 2027, aiming for a market launch in Q3 2027. RP1 is a herpes simplex virus-based therapy modified with a fusogenic protein (GALV-GP R) and GM-CSF to enhance tumor cell destruction, increase immunogenic cell death, and promote a systemic anti-tumor immune response. The FDA has awarded Breakthrough Therapy Designation (BTD) for RP1 in combination with nivolumab for adults with advanced melanoma that has progressed after anti-PD1 treatment. In June 2025, Replimune shared updated results from the IGNYTE study (RP1 + nivolumab in anti-PD1-refractory melanoma) at the 2025 ASCO Annual Meeting. Darovasertib (IDE196) is a potent, selective PKC inhibitor in clinical development. PKC lies downstream of the GNAQ and GNA11 pathways. Darovasertib is currently in a Phase III trial for primary non-metastatic uveal melanoma, a Phase II/III (DAR-UM-2) study for HLA-A2-negative metastatic uveal melanoma (MUM), and other Phase II trials in ocular melanoma. The company expects results from the pivotal DAR-UM-2 trial in first-line HLA-A2-negative MUM by late 2025. In March 2025, the FDA granted BTD to darovasertib for neoadjuvant treatment of primary uveal melanoma patients recommended for enucleation. The anticipated launch of these emerging melanoma therapies are poised to transform the Melanoma market landscape in the coming years. As these cutting-edge melanoma therapies continue to mature and gain regulatory approval, they are expected to reshape the melanoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for melanoma, visit @ Melanoma Management Melanoma Market Dynamics The melanoma market dynamics are anticipated to change in the coming years. Drugs like OPDIVO and KEYTRUDA, particularly in combination with ipilimumab, have significantly improved overall survival and achieved durable response rates (~30–40%) in metastatic melanoma; however, the limited long-term efficacy in many patients highlights the urgent need for effective second-line therapies and continued innovation. With nearly 50% of melanoma patients harboring BRAF mutations, targeted therapy has become a viable option, while molecular profiling enables patient stratification even in refractory settings for clinical trials and off-label interventions. Moreover, targeting underrepresented melanoma subtypes such as uveal, mucosal, and acral presents opportunities for market expansion and accelerated regulatory pathways, given the high unmet need and paucity of existing therapies. Furthermore, many potential therapies are being investigated for the treatment of melanoma, and it is safe to predict that the treatment space will significantly impact the melanoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the melanoma market in the 7MM. However, several factors may impede the growth of the melanoma market. Moreover, melanoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the melanoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the melanoma market growth. Melanoma Report Metrics Details Study Period 2020–2034 Melanoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Melanoma Companies Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others Key Melanoma Therapies Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab, and others Scope of the Melanoma Market Report Melanoma Therapeutic Assessment: Melanoma current marketed and emerging therapies Melanoma Market Dynamics: Conjoint Analysis of Emerging Melanoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Melanoma Market Access and Reimbursement Discover more about melanoma drugs in development @ Melanoma Clinical Trials Table of Contents 1. Melanoma Market Key Insights 2. Melanoma Market Report Introduction 3. Melanoma Market Overview at a Glance 4. Melanoma Market Executive Summary 5. Disease Background and Overview 6. Melanoma Treatment and Management 7. Melanoma Epidemiology and Patient Population 8. Patient Journey 9. Melanoma Marketed Drugs 10. Melanoma Emerging Drugs 11. Seven Major Melanoma Market Analysis 12. Melanoma Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis Related Reports Melanoma Pipeline Melanoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key melanoma companies, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, among others. Ocular Melanoma Market Ocular Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ocular melanoma companies, including Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., among others. Uveal Melanoma Market Uveal Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveal melanoma companies, including Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, among others. Metastatic Melanoma Market Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies, including Cancer Insight LLC, Elios Therapeutics LLC, Evaxion Biotech A/S, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, InxMed (Shanghai) Co. Ltd., Aivita Biomedical Inc., Hoffmann-La Roche, Idera Pharmaceuticals, Iovance Biotherapeutics Inc., Eisai Inc., Biocad, Myrexis Inc., Pain Therapeutics, Altor BioScience, among others. Refractory Metastatic Melanoma Market Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory metastatic melanoma companies, including BioNTech SE, Y-mAbs Therapeutics, Seagen Inc., among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter CONTACT: Contact Us Shruti Thakur info@ +14699457679 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON, July 25, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Proteomics: Technologies and Global Markets" was valued at $27.6 billion in 2024 and is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030. The report offers a detailed analysis of the global market for proteomic technologies, segmented by product type (instruments and software, consumables), platform (mass spectrometry, biochip), application (drug discovery and development, research, diagnostics, applied proteomics), and region (North America, Europe, Asia-Pacific, and Rest of the World). Protein structural analysis and protein-expression products are outside the scope of the report. The study discusses market trends, challenges, and emerging technologies, while also examining the competitive landscape and the market shares of leading vendors. It includes a section on ESG trends and provides company profiles that include insights into financials, product portfolios, and recent advances. This analysis serves as a valuable resource for understanding strategic opportunities and market dynamics in the evolving proteomics sector. This report is particularly relevant today due to the growing demand for innovative and personalized therapies, which is driving advances in proteomic technologies. Increased investments in R&D are accelerating the discovery of new biomarkers, which are crucial for early and accurate diagnosis of diseases. These trends underscore the importance of proteomics in shaping the future of precision medicine and improving healthcare outcomes. The factors driving the market's growth include: Increasing Investments in R&D: Governments, biotech firms, and academic institutions are increasing funding in proteomics research to drive innovation in diagnostics, drug discovery, and therapeutic development. Transition Towards Personalized Medicine: Proteomics enables the identification of protein biomarkers that support tailored treatments based on individual biological profiles, making it a cornerstone in the shift toward personalized healthcare. Aging Population and Prevalence of Chronic Diseases: As the global population ages, chronic conditions like cancer and cardiovascular diseases are becoming more common, increasing the demand for proteomics tools that aid in early detection and targeted treatment. Emerging Technologies: Advances such as high-resolution mass spectrometry, AI-driven data analysis, and single-cell proteomics are accelerating research making it more precise, and cost-effective, thereby expanding the scope and impact of proteomics. Request a sample copy of the global market for proteomic technologies report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $27.6 billion Market size forecast $57.2 billion Growth rate CAGR of 13.0% from 2025 to 2030 Segments covered Platform, Application, Product Type and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, Japan, China, India, South Korea, Rest of Asia-Pacific, and Rest of Europe Market drivers Increasing investments in R&D. Transition towards personalized medicine. Aging population and growing prevalence of chronic diseases. Emerging technologies. Interesting facts: Advances in Technology: The market has seen notable progress in mass spectrometry, particularly with improvements in software and automation that streamline essential processes like sample preparation. Innovation from Emerging Companies: Start-up companies such as Nautilus and SomaLogic have introduced innovative platforms that are expected to reshape the market's future. Emerging startup: Alamar Biosciences Nautilus Biotechnology Pixelgen Technologies Syncell Inc. Sengenics The report addresses the following questions: What is the projected size and growth rate of the market?- The global proteomics market was valued at $27.6 billion in 2024 and is expected to grow at a CAGR of 13% to reach $57.2 billion by the end of 2030. Which factors are driving the growth of the market?- The global market of proteomic technologies is growing due to the rising aging population and growing prevalence of chronic diseases, increasing investments in R&D and in the biotechnology sector, and rising demand for personalized medicine. Which market segments are covered in the report?- The global market for proteomic technologies is segmented based on platform, product type, application, and region. Which platform type will be dominant through 2030?- The mass spectrometry segment will be dominant through 2030. Which region has the largest market share?- North America holds the largest share of the market. Market Leaders include: AGILENT TECHNOLOGIES INC. ARRAYIT CORP. BIO-RAD LABORATORIES INC. BIO-TECHNE BRUKER CREATIVE PROTEOMICS DANAHER CORP. JEOL LTD. MERCK KGAA PROMEGA CORP. REVVITY SHIMADZU CORP. STANDARD BIOTOOLS THERMO FISHER SCIENTIFIC INC. WATERS CORP. Related reports: Single-Cell Genomics and Proteomics: Emerging Technologies and Markets: This report reviews the single-cell genomics and proteomics market, highlighting its current landscape and future potential. It examines key market drivers, challenges, and opportunities, and segments the market by product type (genomics, epigenomics, transcriptomics), application areas (oncology and immunology), end users (academic institutions and biotech companies), and regions (North America, Europe, Asia-Pacific, and the Rest of the World). It also includes profiles of major companies, covering their business segments, financials, product offerings, and recent developments. Global Multiomics Market: This report provides a detailed analysis of the global multiomics market, focusing on products, platforms, applications, end-users, and regions. It explores market trends and forecasts, along with insights into major players and geographic opportunities. The report also includes strategic tools like PESTEL and ESG analysis, competitive assessments, and recommendations to help companies plan effectively. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
